GLTO Logo

Galecto, Inc. (GLTO) 

NASDAQ$4.05
Market Cap
$5.33M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
603 of 924
Rank in Industry
346 of 527

GLTO Insider Trading Activity

GLTO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$11,6173100

Related Transactions

Firmani LoriInterim CFO0$01$1,469$-1,469
Winslow GarrettGeneral Counsel0$01$2,638$-2,638
Schambye Hans T.Chief Executive Officer0$01$7,510$-7,510

About Galecto, Inc.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 â€¦

Insider Activity of Galecto, Inc.

Over the last 12 months, insiders at Galecto, Inc. have bought $0 and sold $11,617 worth of Galecto, Inc. stock.

On average, over the past 5 years, insiders at Galecto, Inc. have bought $14.71M and sold $1.22M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $10,750 was made by Schambye Hans T. (Chief Executive Officer) on 2022‑03‑22.

List of Insider Buy and Sell Transactions, Galecto, Inc.

2025-01-03SaleSchambye Hans T.Chief Executive Officer
1,341
0.1037%
$5.60$7,510-17.72%
2025-01-03SaleWinslow GarrettGeneral Counsel
471
0.0364%
$5.60$2,638-17.72%
2025-01-03SaleFirmani LoriInterim CFO
261
0.0203%
$5.63$1,469-17.72%
2023-08-15SaleORBIMED ADVISORS LLC10 percent owner
822,680
3.5684%
$0.75$617,010-7.48%
2023-07-31SaleORBIMED ADVISORS LLC10 percent owner
209,400
0.8023%
$3.00$628,200-79.55%
2023-07-25SaleORBIMED ADVISORS LLC10 percent owner
39,200
0.1462%
$2.92$114,464-79.34%
2023-07-13SaleORBIMED ADVISORS LLC10 percent owner
194,700
0.7339%
$2.40$467,280-74.19%
2023-04-17SaleORBIMED ADVISORS LLC10 percent owner
12,429
0.0461%
$1.97$24,485-66.21%
2023-04-17SaleORBIMED ADVISORS LLC10 percent owner
13,089
0.0485%
$1.97$25,785-66.21%
2023-04-14SaleORBIMED ADVISORS LLC10 percent owner
39,355
0.1501%
$1.86$73,200-63.13%
2023-04-14SaleORBIMED ADVISORS LLC10 percent owner
41,446
0.158%
$1.86$77,090-63.13%
2023-04-13SaleORBIMED ADVISORS LLC10 percent owner
13,243
0.0519%
$1.82$24,102-61.26%
2023-04-13SaleORBIMED ADVISORS LLC10 percent owner
13,946
0.0546%
$1.82$25,382-61.26%
2023-04-12SaleORBIMED ADVISORS LLC10 percent owner
2,363
0.0093%
$1.81$4,277-60.83%
2023-04-11SaleORBIMED ADVISORS LLC10 percent owner
13,946
0.0543%
$1.82$25,382-61.41%
2023-04-10SaleORBIMED ADVISORS LLC10 percent owner
51,228
0.1984%
$1.79$91,698-60.81%
2023-04-06SaleORBIMED ADVISORS LLC10 percent owner
9,665
0.0396%
$2.00$19,330-62.87%
2023-04-05SaleORBIMED ADVISORS LLC10 percent owner
92,965
0.3672%
$2.18$202,664-67.11%
2022-03-22PurchaseSchambye Hans T.Chief Executive Officer
5,000
0.0194%
$2.15$10,750-12.79%
2022-03-22PurchaseLindmark BertilChief Medical Officer
14,604
0.057%
$2.16$31,545-12.79%
Total: 33
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Schambye Hans T.Chief Executive Officer
3397
0.2579%
$13,757.8531<0.0001%
Winslow GarrettGeneral Counsel
1009
0.0766%
$4,086.4521<0.0001%
Khuong Chau Quang
2579657
195.8752%
$10.45M10
Novo Holdings A/S10 percent owner
2497791
189.6591%
$10.12M10
Christgau Stephandirector
546136
41.4685%
$2.21M10
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$18,881,323
88
-48.96%
$4.47M
$296,936
37
-18.12%
$4M
$523,320
24
94.37%
$7.01M
$31,129
22
-11.96%
$6.19M
$51,865
17
-38.70%
$6.16M

GLTO Institutional Investors: Active Positions

Increased Positions5+38.46%20,188+15.69%
Decreased Positions5-38.46%6,782-5.27%
New Positions3New12,819New
Sold Out Positions3Sold Out384Sold Out
Total Postitions13company.total142,062+10.42%

GLTO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Novo Holdings A/S$438.009.99%99,91300%2024-12-31
Renaissance Technologies Llc$66.001.5%15,044-6,338-29.64%2024-12-31
Squarepoint Ops Llc$56.001.27%12,701+12,701New2024-12-31
Ubs Group Ag$55.001.25%12,467+7,368+144.5%2024-12-31
Bank Of America Corp /De/$5.000.12%1,226+<1+0.08%2024-12-31
Blackrock, Inc.$2.000.05%49000%2024-12-31
Morgan Stanley$00.01%100-60-37.5%2024-12-31
Jpmorgan Chase & Co$00.01%100+100New2024-12-31
Sbi Securities Co., Ltd.$0<0.01%18+18New2024-12-31
Group One Trading Llc$00%300%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.